retatrutide diarrhea (“reta”) is an experimental weight-loss drug currently in Phase 3 clinical trials. It's a once-weekly injection similar to Ozempic and Mounjaro—but more powerful. The reason comes down to how it works Extreme Side Effects Followed Overdose

In this six-month prospective cohort study, 200 adults ages 18 to 65 with a BMI of 25 kg/m or higher (classified as overweight or obese) were enrolled and prescribed either the GLP-1 receptor agonist semaglutide or the dual GLP-1/GIP agonist tirzepatide

Below is an overview of the key GLP-1 therapies that have shaped the current market landscape: Mounjaro Shakes Up Indias GLP-1 Market Eli Lillys Mounjaro (Tirzepatide) has officially entered the Indian market as the first GLP-1 and GIP (Glucose-Dependent Insulinotropic Polypeptide) dual agonist, marking a significant breakthrough in the treatment of type 2 diabetes and obesity

Naturecan's GLP-1 support range uses transparent formulations and third-party tested ingredients for this reason

There's no standardized microdosing protocol yet that's part of why this conversation is still emerging

If you are considering GLP 1 medications or have already started treatment, here is what you should know about hair loss and how to reduce your risk while still making progress toward your goals

Most users report maintained or slightly reduced gym performance during the initial 8-12 weeks as the body adjusts to caloric deficit and medication effects